← All trials
NCT02047994
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2016
- Primary completion
- Dec 1, 2033
- Completion date
- Dec 1, 2035
- First posted
- —
- Last posted
- —
- Enrollment
- 30000
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- International Agency for Research on CancerLead sponsor
- University of LatviaOverall official - principal investigator
- Vanderbilt UniversityCollaborator
- University of LatviaCollaborator
- Latvian Biomedical Research and Study CentreCollaborator
- Technion UniversityCollaborator
- Karolinska InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.